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Abstract We examined whether the mitogen-activated protein
kinase (MAPK) pathway is involved in Shiga toxin (Stx)-induced
Vero cell injury. Consonant with cell injury, Stx caused a
transient extracellular signal-regulated kinase1/2 (ERK1/2) and
a sustained p38 MAPK phosphorylation. p38 MAPK inhibitors
(SB 203580 and PD 169316), but not an ERK1/2 kinase inhibitor
(PD 98059), partially inhibited the Stx-induced cell death.
BAPTA-AM, a Ca2+ chelator, reduced both cell injury and p38
MAPK phosphorylation. Antioxidants reduced Stx1-induced p38
MAPK phosphorylation. These data indicate that Stx activates
p38 MAPK through an increase in intracellular Ca2+ and
reactive oxygen species, and this signaling is involved in Stx-
induced cell death. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Shiga toxins (Stxs) are a family of bacterial protein toxins
produced by Shigella dysenteriae type 1 and enterohemorrhag-
ic Escherichia coli (Stx-producing E. coli). The Stx family is
classi¢ed into two groups on the basis of immunological prop-
erty, namely the Stx1 family and the Stx2 family. Stx1 has
about 60% homology to Stx2 at the amino acid level. Stxs are
composed of one enzymatically active A subunit responsible
for RNA N-glycosidase activity, thereby inhibiting protein
synthesis, and ¢ve B subunits which carry the binding prop-
erty of holotoxin to receptor molecule such as globotriaosyl
ceramide (Gb3) and globotetraosyl ceramide (Gb4). There-
fore, Stx was originally thought to cause cell death by inhib-
iting protein synthesis [1]. However, recent observations indi-
cate that the situation is more complex. Addition of B
subunit, which had been thought to have no e¡ect on protein
synthesis, to Burkitt’s lymphoma cells induced cell death [2].
Yoshida et al. also observed that cycloheximide, an inhibitor
of protein synthesis, did not cause apoptosis in human endo-
thelial cells that underwent apoptosis due to Stx [3]. These
reports suggest that inhibition of protein synthesis is not the
sole cause of Stx-induced cell death, and that Stx exerts cell
injury through a more complex mechanism.
The mitogen-activated protein kinase (MAPK) family has
an important role in signal transduction and its pathway is
activated by a variety of stimuli, such as growth factors and
cellular stresses [4^7]. Among the MAPK family, three mem-
bers in particular, the extracellular signal-regulated kinases
(ERKs), c-Jun NH2-terminal kinases (JNKs, also called
SAPKs), and p38 MAPK, have been well characterized. Acti-
vation of the ERK signaling pathway functions to protect
cells from a variety of cellular stresses. By contrast, the
JNK and p38 MAPK signaling pathways have been suggested
to be pathways of cell death [8,9]. Recently, Katagiri et al.
have demonstrated that Stx activates the Src family kinase,
Yes, which is thought to be an upstream player of MAPK
activation [10]. However, to date, there is no direct evidence
linking MAPK family members with the signaling pathway of
Stx-induced cell injury.
Ca2-mobilizing compounds, including A23187 and thapsi-
gargin, have been shown to induce cell death in a certain type
of cells [11,12]. It has also been observed that Stx increased
the intracellular Ca2 concentration and that inhibition of this
increase reduced Stx cytotoxicity [2,13], suggesting that an
increase in cellular Ca2 may be involved in Stx-induced cell
death. However, it is not yet clear where this pathway is
positioned in Stx-induced intracellular signal transduction.
In the present study, we show that Stx1 and Stx2 induce
phosphorylation of both ERK1/2 and p38 MAPK, and that
Stx-induced Vero cell death is partially associated with the
p38 MAPK pathway but not with the ERK pathway. We
also provide evidence that cellular Ca2 has an important
role as an upstream molecule of p38 MAPK.
2. Materials and methods
2.1. Puri¢cation of Stxs
Stx1 and Stx2 were prepared and puri¢ed as described previously
[14,15]. A non-toxic mutant Stx1, E167Q, in which glutamic acid at
position 167 from the N-terminus of the A subunit of Stx1 is replaced
by glutamine was prepared and puri¢ed as described previously [16].
2.2. Cell culture
Vero cells were grown and maintained in Eagle minimum essential
medium (MEM; Gibco BRL) supplemented with 100 U/ml penicillin,
100 Wg/ml streptomycin, 8 Wg/ml tyrosine and 10% fetal bovine serum
(FBS). All experiments were performed after serum starvation. Cells
were grown to 80% con£uence in MEM containing 10% FBS and
transferred to MEM containing 0.5% FBS for 48^72 h.
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2.3. Measurement of cell viability
Cell viability was determined by the 4-[3-(4-iodophenyl)-2-(4-nitro-
phenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) assay [17].
Quiescent Vero cells were incubated with Stx in the presence or ab-
sence of test agent (s) for 24 or 48 h and a mixture of WST-1 and 1-
methoxy-5-methylphenazinium methosulfate was then added to each
well (¢nal concentrations: WST-1, 0.5 mM; 1-methoxy-5-methylphe-
nazinium methosulfate, 0.02 mM). After incubation for 1 h, the ab-
sorbance was measured at 405 nM with a reference wavelength of 655
nm.
2.4. Evaluation of phosphorylation of ERK1/2 and p38 MAPK
In preliminary experiments, MAPK activity was assessed by in vitro
kinase assay. As the activity had been comparable to that obtained by
evaluating phosphorylation of MAPK, we assessed activation of
MAPK by Western blotting with anti-phospho-MAPK antibody.
Brie£y, quiescent Vero cells were stimulated with Stx in the absence
or presence of test agent (s), and were rinsed quickly in 100-mm dishes
with ice-cold Tris-bu¡ered saline (TBS; 25 mM Tris, pH 7.4, 150 mM
NaCl) containing 1 mM Na3VO4 and then lysed in lysis bu¡er (50
mM Tris, pH 7.4, 50 mM NaCl, 50 mM NaF, 5 mM EDTA, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS), 1 mM Na3VO4, 2 mM PMSF, 10 Wg/ml leupeptin, 10 Wg/ml
antipain, 100 Wg/ml benzamidine, 10 Wg/ml aprotinin, 100 Wg/ml soy-
bean trypsin inhibitor, 1% glycerol) for 20 min at 4‡C. The cells were
then scraped o¡ the dish, centrifuged at 12 000Ug for 10 min, and the
protein concentration in the supernatants was determined by DC
protein assay (Nippon, Bio-Rad). The remaining supernatants were
combined with 4USDS^PAGE sample bu¡er (0.5 M Tris, pH 6.8,
50% glycerol, 8% SDS, 0.4 M dithiothreitol, 0.05% bromophenol
blue) and heated at 95‡C for 3 min. The samples were then frozen
at 380‡C until use.
After separation by SDS^PAGE, the proteins were transferred to
nitrocellulose membranes and analyzed by immunoblotting. The
membranes were incubated in blocking solution and then with pri-
mary antibodies for 1.5 h at 37‡C. Excess primary antibody was
removed by washing the membranes in TBS containing 0.05% Tween
20. The blots were incubated with appropriate secondary antibodies
for 1 h at 37‡C, and the membranes were then washed and proteins
associated with antibodies were detected by the enhanced chemilumi-
nescence detection system (Amersham Pharmacia Biotech). For re-
peated immunoblotting, the membranes were stripped in 50 mM
Tris, pH 6.5, 100 mM 2-mercaptoethanol and 2% SDS for 30 min
at 50‡C.
2.5. Chemicals and reagents
Rabbit polyclonal anti-phospho-ERK1/2 antibody speci¢c for dual-
phosphorylated 202Thr and 204Tyr of ERK1/2, rabbit polyclonal anti-
phospho-p38 MAPK antibody speci¢c for dual-phosphorylated
180Thr and 182Tyr of p38 MAPK, and rabbit polyclonal anti-p38
MAPK antibody which detects phosphorylation-state independent
p38 MAPK, were purchased from New England Biolabs Inc. Horse-
radish peroxidase-conjugated sheep anti-mouse and donkey anti-rab-
bit secondary antibodies were obtained from Amersham Pharmacia
Biotech. PD 98059, SB 203580, PD 169316, thapsigargin, A23187 and
1,2-bis(o-aminophenoxy)ethane-N,N,NP,NP-tetraacetic acid tetra(ace-
toxymethyl) ester (BAPTA-AM) were obtained from Calbiochem,
and were dissolved in 100% DMSO and diluted with culture medium
to the ¢nal concentration (1% DMSO). All other chemicals and re-
agents were purchased from Sigma Chemical Co. or Wako Pure
Chemicals.
3. Results
3.1. Stx-induced cell injury
The cytotoxic e¡ects of Stx1, Stx2 and E167Q in Vero cells
were determined by the WST-1 assay. Quiescent Vero cells
were incubated with various concentrations of Stx1, Stx2 or
E167Q for 24 or 48 h. Both Stx1- and Stx2-reduced cell via-
bility in a dose- and time-dependent manner. The 50% cyto-
toxic concentrations for 48 h of treatment with Stx1 or Stx2
were 11 pg/ml and 1.3 pg/ml, respectively. In contrast, 1 Wg/ml
E167Q reduced cell viability by only 30%, indicating that
E167Q had a much weaker e¡ect, about 1/105 as reported
by us previously [16], on Vero cell viability.
3.2. Stx1 induces phosphorylation of MAPK
When quiescent Vero cells were stimulated with 3 ng/ml
Stx1, marked phosphorylations of ERK1/2 and p38 MAPK
were observed (Fig. 1). Both phosphorylations peaked at 2 h
of Stx1 stimulation, and ERK1/2 phosphorylation then de-
clined to the basal level and p38 MAPK phosphorylation
was sustained thereafter. In contrast, Stx1 had little e¡ect
on the MAPK protein level (Fig. 1A,C). Fig. 1B,D represents
the dose-dependent e¡ect of Stx1 on both MAPK phosphor-
ylations. At a concentration of 3 pg/ml or more, Stx1 induced
phosphorylations of ERK1/2 and p38 MAPK.
3.3. Phosphorylation of MAPK by Stx2 but not by E167Q
When quiescent Vero cells were stimulated with various
concentrations of Stx2 for 2 h, phosphorylations of ERK1/2
and p38 MAPK were also observed (Fig. 2A,B). At an Stx2
concentration of 30 pg/ml or more, the ERK1/2 phosphory-
lation level was comparable to that observed with 300 pg/ml
Fig. 1. E¡ect of Stx1 on phosphorylation of ERK1/2 and p38
MAPK. A and C: Typical examples of Stx1-induced ERK1/2 (A)
and p38 MAPK phosphorylation (C) in a time-dependent manner
by Western blot analysis (WB). Quiescent Vero cells were incubated
with 3 ng/ml Stx1 for the time indicated. An equal amount of pro-
tein was subjected to SDS^PAGE in a 11% acrylamide gel and im-
munoblotted with anti-phospho-ERK1/2 antibody or -p38 MAPK
antibody (upper panel). The same membrane was then stripped and
reprobed with anti-ERK1/2 or -p38 MAPK antibody (lower panel).
B and D: Typical example of Stx1-induced dose-dependent ERK1/2
(B) and p38 MAPK phosphorylation (D). Quiescent Vero cells were
incubated with Stx1 at the indicated concentration for 2 h. Similar
results were obtained in three separate experiments.
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Stx1. The p38 MAPK phosphorylation level in response to
300 pg/ml Stx2 was also larger than that with the same dose
of Stx1. This indicates that Stx2 phosphorylates ERK1/2 and
p38 MAPK more potently than Stx1, and this e⁄cacy was
proportional with that observed in the cell viability determi-
nation. The protein levels of both MAPKs were not signi¢-
cantly a¡ected by treatment with Stx2. When 300 pg/ml Stx2
was applied to the cells for 10 or 30 min, phosphorylation
levels of ERK1/2 and p38 MAPK were minimal (data not
shown). Therefore, the time courses of phosphorylations of
ERK1/2 and p38 MAPK in response to Stx2 were similar to
those of Stx1-induced phosphorylations.
When quiescent Vero cells were stimulated with 10 or 100
ng/ml E167Q known to be a non-toxic Stx1 mutant for 2 h,
phosphorylations of ERK1/2 and p38 MAPK were not ob-
served (Fig. 2C,D). This result was consistent with the data
from the cell viability experiment.
3.4. E¡ects of p38 MAPK inhibitors on Stx1-induced cell
responses
The e¡ects of SB 203580 and PD 169316, both inhibitors of
p38 MAPK [18,19], on Stx1-induced cell injury were examined
by the WST-1 assay. To this end, we used a concentration of
20 pg/ml, because this dose of Stx1 fully activated p38 MAPK
and induced cell death. Quiescent Vero cells were pretreated
with each agent for 1 h, and 20 pg/ml Stx1 was then added to
the cells in the presence of each drug. As shown in Fig. 3, 30
WM SB 203580 and 3 WM PD 169316 partially but signi¢-
cantly reduced Stx1-induced cell injury. 3 WM SB 203580
had no inhibitory e¡ect on Stx1-induced cell injury. On the
contrary, it signi¢cantly enhanced cell injury. Although the
exact reason for this enhancement is not clear, the following
might be one possible explanation. When the cells were
treated with 30 WM SB 202474 whose structure is related to
SB 203580 [18], but which lacks the inhibitory activity of p38
MAPK, instead of 3 WM SB 203580, we observed a response
similar to that with 3 WM SB 203580 (vehicle; 26.5 þ 2.5%, 30
WM SB 202474; 17.6 þ 4.9%, in duplicate and repeated three
times, P6 0.05). Therefore, it is conceivable that this enhance-
ment of Stx1-induced cell injury was due to the inert molecule
of this analogue.
To determine the inhibitory e¡ect of 30 WM SB 203580 and
3 WM PD 169316 on p38 MAPK, quiescent Vero cells were
incubated with each drug for 1 h, and were then stimulated
with 20 pg/ml Stx1 for 2 h in the presence of drug. As shown
in Fig. 3C, each drug reduced phosphorylation of p38 MAPK.
Fig. 2. E¡ects of Stx2 and E167Q on phosphorylations of ERK1/2
or p38 MAPK. A and B: Typical example of Stx2-induced ERK1/2
(A) or p38 MAPK phosphorylation (B) by Western blot analysis.
Quiescent Vero cells were incubated with Stx1 or Stx2 at the indi-
cated concentration for 2 h. C and D: Typical example of the e¡ect
of E167Q on ERK1/2 (C) or p38 MAPK phosphorylation (D). Qui-
escent Vero cells were incubated with Stx1 or E167Q at the indi-
cated concentration for 2 h. Similar results were obtained in three
separate experiments.
Fig. 3. E¡ects of p38 MAPK inhibitors on Stx1-induced cell injury
and phosphorylation of p38 MAPK. A and B: Quiescent Vero cells
were incubated with or without SB 203580 (A) or PD 169316 (B) at
the indicated concentration for 1 h. Cells were then treated with or
without 20 pg/ml Stx1 for 24 h in the presence of drug. Data are
expressed as percent of the mean value obtained from cells un-
treated (with both Stx and test agents). Values are presented as
mean þ S.D. from four independent experiments performed in dupli-
cate. * and *** represent the signi¢cance level of P6 0.05 and
P6 0.001, respectively, tested for the di¡erence between vehicle and
test agents (Dunnett’s method). C: Typical example of the e¡ect of
SB 203580 (30 WM) or PD 169316 (3 WM) on Stx1-induced p38
MAPK phosphorylation by Western blot analysis. Similar results
were obtained in two separate experiments.
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The e¡ect of PD 98059, a speci¢c inhibitor of ERK1/2 ki-
nase [20], on Stx1-induced cell injury was also examined by
the WST-1 assay. Quiescent Vero cells were incubated with
di¡erent doses of PD 98059 and Stx1 for 24 and 48 h. We cold
not detect any signi¢cant e¡ect of PD98059 on Stx1-induced
cell injury (data not shown).
3.5. E¡ect of Ca2+ chelator on Stx1-induced cell responses
Next, we examined the e¡ect of the intracellular Ca2 che-
lator, BAPTA-AM, on Stx1-induced phosphorylation of p38
MAPK. Quiescent Vero cells were incubated with each drug
for 1 h, and were then stimulated with 20 pg/ml Stx1 for 2 h in
the presence of drug. As shown in Fig. 4A, treatment of the
cells with BAPTA-AM reduced phosphorylation of p38
MAPK to the basal level.
The e¡ect of BAPTA-AM on Stx1-induced cell injury was
also examined by the WST-1 assay. Quiescent Vero cells were
pretreated with BAPTA-AM for 1 h and 20 pg/ml Stx1 was
then added to the cells in the presence of drug. As shown in
Fig. 4B, BAPTA-AM markedly reduced Stx1-induced cell in-
jury.
To examine the phosphorylation of p38 MAPK by intra-
cellular Ca2 elevation, quiescent Vero cells were stimulated
with 1 WM A23187 or 30 nM thapsigargin, both of which are
Ca2-mobilizing compounds, for 2 h. As shown in Fig. 4C,
each drug induced phosphorylation of p38 MAPK, while the
protein level of p38 MAPK was not signi¢cantly a¡ected by
each treatment.
3.6. E¡ects of antioxidants on Stx1-induced p38 MAPK
phosphorylation
The e¡ects of N-acetyl cysteine (N-Ac) and vitamin E, both
of which are antioxidants, on Stx1-induced p38 MAPK phos-
phorylation were examined. Quiescent Vero cells were incu-
bated with 10 mM N-Ac or 100 WM vitamin E for 1 h, and
were then stimulated with 20 pg/ml Stx1 for 2 h in the pres-
ence of drug. As shown in Fig. 5, each drug reduced Stx1-
induced p38 MAPK phosphorylation, while the protein level
of p38 MAPK was not signi¢cantly a¡ected by each treat-
ment.
4. Discussion
In the present study, the intracellular signaling pathway
activated by Stx1 and Stx2 in Vero cells was examined.
Stx1, Stx2, but not E167Q were shown to cause cell injury.
Concurrent with cell injury, Stx1 and Stx2 clearly induced
sustained phosphorylation of p38 MAPK. The p38 MAPK
inhibitors, SB203580 and PD 169316 partially prevented the
Stx1-induced cell injury. Stx1 and Stx2 also caused phosphor-
ylation of ERK1/2, but the phosphorylation peaked at 2 h of
Stx1 stimulation and then declined to the basal level. PD
98059, an ERK1/2 kinase inhibitor, did not prevent or poten-
tiate the Stx1-induced cell injury. These results suggest that
the activation of p38 MAPK plays a role in Stx-induced cell
death.
Stx is composed of one enzymatically active A subunit re-
sponsible for Stx-induced inhibition of protein synthesis and
¢ve B subunits which carry the binding property of the hol-
otoxin [1]. A mutant Stx1 with a single mutation at position
167 from the N-terminus of the A subunit of Stx1, glutamic
acid being replaced by glutamine (E167Q) has been shown to
have little activity in both cytotoxicity to Vero cells and in-
hibitory activity of protein synthesis [16]. The present study
showed that E167Q caused neither cell injury nor phosphor-
ylation of p38 MAPK, suggesting that an intact A subunit is
necessary for the phosphorylation of p38 MAPK.
It is well known that reactive oxygen species (ROS) activate
p38 MAPK [21^23]. Recently, King et al. have described that
oxygen free radical production by polymorphonuclear cells is
Fig. 4. E¡ect of intracellular Ca2 chelator on Stx1-induced cell in-
jury and phosphorylation of p38 MAPK A: Typical example of the
e¡ect of BAPTA-AM (BAPTA) on Stx1-induced p38 MAPK phos-
phorylation by Western blot analysis. Similar results were obtained
in three separate experiments. B: E¡ect of BAPTA-AM on Stx1-in-
duced cell injury. Quiescent Vero cells were incubated with or with-
out BAPTA-AM at the indicated concentration for 1 h and were
then stimulated with or without 20 pg/ml Stx1 in the presence of
drug. Data are expressed as percent of the mean value obtained
from cells untreated (with both Stx and test drug). Values are pre-
sented as mean þ S.D. from two independent experiments performed
in duplicate. * and ** represent the signi¢cance level of P6 0.05
and P6 0.01, respectively, tested for the di¡erence between vehicle
and test agents (Dunnett’s method). C: Typical example of A23187-
or thapsigargin-induced p38 MAPK phosphorylation by Western
blot analysis. Similar results were obtained in two separate experi-
ments.
Fig. 5. E¡ects of antioxidants on Stx1-induced p38 MAPK phos-
phorylation. Typical example of the e¡ect of N-Ac or vitamin E on
Stx1-induced p38 MAPK phosphorylation by Western blot analysis.
Quiescent Vero cells were incubated with 10 mM N-Ac, 100 WM vi-
tamin E, or 1% ethanol (EtOH, vehicle for vitamin E) for 1 h, and
were then stimulated with 20 pg/ml Stx1 for 2 h in the presence of
drug. Similar results were obtained in two separate experiments.
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observed 30 min after addition of Stx1 [24]. Matsunaga et al.
have also observed that treatment of human aortic endothelial
cells with Stx1 for 1 h results in increased levels of hydroxyl
radical and that this response is associated with the reduction
of catalase mRNA and protein but with a lesser alteration in
the levels of Cu, Zn-superoxide dismutase and NADPH oxi-
dase mRNA [25]. In the present study, we showed that Stx1-
induced activation of p38 MAPK peaked within 2 h and that
N-Ac and vitamin E inhibited Stx1-induced phosphorylation
of p38 MAPK. These data suggest that Stx1, and possibly the
A subunit of Stx1 in particular, speci¢cally inhibits transcrip-
tion of catalase and produces ROS, leading to activation of
p38 MAPK.
Stx1-induced phosphorylation of p38 MAPK and cell in-
jury were inhibited by treatment with intracellular Ca2 che-
lator. In addition, Ca2-mobilizing compounds including
A23187 and thapsigargin induced phosphorylation of P38
MAPK in Vero cells. Although we did not perform direct
measurement of intracellular Ca2 concentration, these results
suggest that Stx1 elevated the intracellular Ca2 concentration
and that this increase triggered the phosphorylation of p38
MAPK and cell injury. This may also be supported by pre-
vious reports that Stx mobilized intracellular Ca2 and the
inhibition of its Ca2 mobilization by extracellular EGTA
or verapamil reduced Stx-induced cytotoxicity [2,13], and,
more recently, that Ca2-mobilizing compounds including
A23187 and thapsigargin have been shown to activate p38
MAPK along with induction of cell death [11].
Recently, Herson et al. clearly indicated that hydrogen per-
oxide increases cellular [NAD] and opens NAD-activated
Ca2-permeable cation channels, causing unregulated Ca2
entry and consequent cell death [26]. Taken together with
this report and our data, the Stx1-induced cell injury cascade
in Vero cells appears to operate as follows: Stx1 activates
ROS production, activating Ca2 entry pathway, leading to
intracellular Ca2 elevation and p38 MAPK activation.
In contrast to p38 MAPK inhibitors, Ca2 chelator was a
more potent inhibitor of Stx1-induced cell injury. Intracellular
Ca2 elevation is also known to activate other signaling path-
ways responsible for cell injury, such as the calpain, calcineur-
in and JNK pathways [27^30]. Therefore, in addition to inhi-
bition of the p38 MAPK pathway, inhibitors of intracellular
Ca2 elevation may suppress other signaling pathways in re-
sponse to Stx. Furthermore, the residual component of Stx-
induced cell injury, which was insensitive to p38 MAPK in-
hibitors, may be due to inhibition of protein synthesis. These
hypotheses need further evaluations.
To our knowledge, this is the ¢rst report that MAPK path-
ways can be activated by Stx1 and Stx2, and that activation of
the p38 MAPK pathway, which is triggered by intracellular
Ca2 elevation, plays a role in Stx-induced cell death.
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